Dregalla Medical Technologies careers

Dregalla Medical Technologies, LLC is investigating a novel, patent pending advancement which may be used bedside at the time of surgery to restore normal, functional tissue. This is achieved by activating regenerative signals present in developmental tissues and as a result, greatly enhance post-operation recovery time, minimize the risk of infection, prevent scar formation, and redevelop the soft tissues to a functional state.

We have developed a new generation of tissue-directed wound repair which accelerates wound healing, minimizes scar tissue and encourages the growth of native tissue (i.e. new skin). This is achieved by using a developmental tissue which is combined with a mixture of pro-growth proteins.

The product falls within a key regulatory field of the Food and Drug Administration, allowing us to enter the market immediately; contract manufacturing and quality control third-party groups are in place for product launch.